Merck Answers USPTO In Singulair Patent Re-Exam
Merck & Co. has responded to an early finding from the U.S. Patent and Trademark Office that its patent covering blockbuster asthma and allergy drug Singulair is invalid, although it may...To view the full article, register now.
Already a subscriber? Click here to view full article